X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abridged index medicus (2) 2
acquired immunodeficiency syndrome - drug therapy (2) 2
acquired immunodeficiency syndrome - ethnology (2) 2
acquired immunodeficiency syndrome - virology (2) 2
adenine - analogs & derivatives (2) 2
adenine - therapeutic use (2) 2
adult (2) 2
algorithms (2) 2
anti-hiv agents - administration & dosage (2) 2
anti-hiv agents - adverse effects (2) 2
anti-hiv agents - therapeutic use (2) 2
antiretroviral drugs (2) 2
antiretroviral therapy (2) 2
benzoxazines - administration & dosage (2) 2
benzoxazines - adverse effects (2) 2
benzoxazines - therapeutic use (2) 2
clinical trials (2) 2
combination therapy (2) 2
deoxycytidine - analogs & derivatives (2) 2
deoxycytidine - therapeutic use (2) 2
dosage and administration (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
efavirenz (2) 2
emtricitabine (2) 2
exanthema (2) 2
female (2) 2
hiv reverse transcriptase - antagonists & inhibitors (2) 2
hiv-1 - drug effects (2) 2
hiv-1 - genetics (2) 2
human immunodeficiency virus--hiv (2) 2
humans (2) 2
index medicus (2) 2
internal medicine (2) 2
lamivudine (2) 2
lipids (2) 2
male (2) 2
medicine, general & internal (2) 2
middle aged (2) 2
mutation (2) 2
nevirapine (2) 2
nitriles - administration & dosage (2) 2
nitriles - adverse effects (2) 2
nitriles - therapeutic use (2) 2
non-nucleoside reverse transcriptase inhibitors (2) 2
nucleosides (2) 2
nucleotides (2) 2
organophosphonates - therapeutic use (2) 2
patient outcomes (2) 2
protease-inhibitor (2) 2
pyrimidines - administration & dosage (2) 2
pyrimidines - adverse effects (2) 2
pyrimidines - therapeutic use (2) 2
regression analysis (2) 2
reverse transcriptase inhibitors - therapeutic use (2) 2
rilpivirine (2) 2
rna-directed dna polymerase (2) 2
tenofovir (2) 2
treatment outcome (2) 2
viral load - drug effects (2) 2
abacavir (1) 1
active antiretroviral therapy (1) 1
adenine - administration & dosage (1) 1
adenine - adverse effects (1) 1
aged (1) 1
antiviral agents (1) 1
cd4 antigen (1) 1
clinical medicine (1) 1
corporate sponsorship (1) 1
creatinine (1) 1
cystatin-c (1) 1
daily lamivudine (1) 1
deoxycytidine - administration & dosage (1) 1
deoxycytidine - adverse effects (1) 1
design (1) 1
dreams (1) 1
drugs (1) 1
efficacy (1) 1
evaluation (1) 1
glomerular filtration (1) 1
glomerular filtration rate (1) 1
guidelines (1) 1
hiv infection (1) 1
hospitals (1) 1
nucleosides - therapeutic use (1) 1
nucleotides - therapeutic use (1) 1
organophosphonates - administration & dosage (1) 1
organophosphonates - adverse effects (1) 1
pharmaceuticals (1) 1
regimens (1) 1
renal blood flow (1) 1
research (1) 1
safety (1) 1
technological change (1) 1
tubular secretion (1) 1
zidovudine (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
07/2013, ISBN 9781118312155, 10
The most important mechanisms for renal excretion of drugs are glomerular filtration and tubular secretion. These mechanisms undergo significant maturational... 
glomerular filtration | glomerular filtration rate (GFR) | tubular secretion | renal blood flow | Renal blood flow | Glomerular filtration rate (GFR) | Glomerular filtration | Tubular secretion
Book Chapter
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.